265 related articles for article (PubMed ID: 17502149)
1. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
2. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
Lin YS; Tungpradit R; Sinchaikul S; An FM; Liu DZ; Phutrakul S; Chen ST
J Med Chem; 2008 Dec; 51(23):7428-41. PubMed ID: 19053781
[TBL] [Abstract][Full Text] [Related]
3. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
Wang Y; Xin D; Liu K; Zhu M; Xiang J
Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
[TBL] [Abstract][Full Text] [Related]
4. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
[TBL] [Abstract][Full Text] [Related]
6. Development of novel water-soluble photocleavable protective group and its application for design of photoresponsive paclitaxel prodrugs.
Noguchi M; Skwarczynski M; Prakash H; Hirota S; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5389-97. PubMed ID: 18440235
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anti-cancer efficacy of rapid hydrolysed water-soluble paclitaxel pro-drugs.
Ryu BY; Sohn JS; Hess M; Choi SK; Choi JK; Jo BW
J Biomater Sci Polym Ed; 2008; 19(3):311-24. PubMed ID: 18325233
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
9. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.
Ansell SM; Johnstone SA; Tardi PG; Lo L; Xie S; Shu Y; Harasym TO; Harasym NL; Williams L; Bermudes D; Liboiron BD; Saad W; Prud'homme RK; Mayer LD
J Med Chem; 2008 Jun; 51(11):3288-96. PubMed ID: 18465845
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety.
Cavallaro G; Maniscalco L; Campisi M; Schillaci D; Giammona G
Eur J Pharm Biopharm; 2007 May; 66(2):182-92. PubMed ID: 17182230
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological activity of protaxols.
Nicolaou KC; Riemer C; Kerr MA; Rideout D; Wrasidlo W
Nature; 1993 Jul; 364(6436):464-6. PubMed ID: 8101355
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA).
Jiang Y; Dipaola RS; Hu L
Bioorg Med Chem Lett; 2009 May; 19(9):2587-90. PubMed ID: 19345094
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
de Groot FM; van Berkom LW; Scheeren HW
J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry.
Gopin A; Ebner S; Attali B; Shabat D
Bioconjug Chem; 2006; 17(6):1432-40. PubMed ID: 17105221
[TBL] [Abstract][Full Text] [Related]
19. Development of first photoresponsive prodrug of paclitaxel.
Skwarczynski M; Noguchi M; Hirota S; Sohma Y; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2006 Sep; 16(17):4492-6. PubMed ID: 16806915
[TBL] [Abstract][Full Text] [Related]
20. O-N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides.
Sohma Y; Hayashi Y; Skwarczynski M; Hamada Y; Sasaki M; Kimura T; Kiso Y
Biopolymers; 2004; 76(4):344-56. PubMed ID: 15386265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
